Diffusion Pharma Wins Patent for its Family of...
Diffusion Pharmaceuticals LLC, a Charlottesville-based clinical-stage drug-development company commercializing drugs utilizing a novel method of action that enhances oxygen diffusion, announced that it has been granted U.S. patent no. 7,351,844 entitled “Bipolar Trans Carotenoid Salts and Their Uses.” This patent includes claims to a family of first-in-class new chemical entities, known as trans biopolar carotenoid (or TBC) molecules. In addition, the company also announced it has been granted corresponding patents from the South African and the New Zealand Patent Offices.
“The issuance of these patents is a vital step in our intellectual property development strategy, furthering our goal of bringing Diffusion Pharmaceutical’s first-in-class therapeutics to market. Our highly unique compounds may one day treat patients with a broad range of disorders involving hypoxia,” said David G. Kalergis, Diffusion’s CEO.
In addition to these newly issued patents, the company has also filed other U.S. patent applications and numerous corresponding foreign and national-stage applications in major international markets.
Diffusion Pharmaceuticals LLC is a clinical-stage drug development company commercializing a family of first-in-class drug candidates to treat serious or life-threatening medical conditions. These proprietary small molecules use a novel method of action to enhance oxygen diffusion to oxygen deprived (hypoxic) tissue. Potential clinical applications include cancer, critical care uses such as trauma, hemorrhage, stroke and heart attack, as well as chronic conditions such as peripheral arterial and vascular disease, cardiovascular disease, and respiratory disorders. Enhanced diffusion of oxygen into hypoxic tissue has an important application in oncology by improving the efficacy of radiation therapy in cancerous tumors. For more information, visit www.diffusionpharma.com.
